Can Psilocybin Help People Quit Smoking?
It may. In this pilot clinical trial at Johns Hopkins, 40.5% of smokers who received a single dose of psilocybin achieved prolonged smoking abstinence at 6 months, compared to just 10% in the nicotine patch group. That means psilocybin gave participants more than six times greater odds of staying smoke-free.
Smoking remains one of the hardest addictions to break. Even with the best available treatments, most people who try to quit end up relapsing within months. Nicotine patches, gums, and prescription medications help some people, but success rates remain frustratingly low. This has pushed researchers to explore unconventional approaches, including psilocybin, the active compound found in certain mushrooms. A team at Johns Hopkins University designed a head-to-head trial to see how psilocybin stacks up against standard nicotine patch therapy for smoking cessation.
Dr. Kumar’s Take
Even as a pilot study, these results are notable. A four-fold difference in quit rates is rare in addiction medicine. Both groups received the same 13 weeks of cognitive behavioral therapy, so the main difference was psilocybin versus the patch. But participants and investigators knew who got which treatment, so expectations could account for some of the gap. The safety profile was also reassuring, with no serious adverse events attributed to psilocybin or the patch. This was a relatively small trial with 82 participants, and larger, multi-site studies are needed before psilocybin becomes a standard treatment. But as a signal of what might be possible, this is hard to ignore.
Study Snapshot
Researchers at Johns Hopkins randomized 82 psychiatrically healthy adult smokers into two groups, and both participants and investigators knew which treatment each person received. One group received a single high dose of psilocybin (30 mg/70 kg body weight) in a supervised clinical setting. The other group received standard nicotine patch therapy. Both groups also participated in 13 weeks of cognitive behavioral therapy specifically designed for smoking cessation. Because everyone got the same behavioral support, the comparison focused on psilocybin versus the patch. The primary outcome was prolonged smoking abstinence at 6 months, a rigorous measure that requires sustained quitting rather than just a single point of success.
Results in Context
The results were striking. At the 6-month mark, 40.5% of participants in the psilocybin group had achieved prolonged smoking abstinence. In the nicotine patch group, only 10% managed to stay smoke-free over that same period. This translates to more than six times greater odds of sustained abstinence for the psilocybin group. To put that in perspective, most FDA-approved smoking cessation treatments improve quit rates by about two to three times compared to placebo. A six-fold advantage, even in a small pilot, is a remarkable signal.
Safety was another encouraging finding. No serious adverse events were attributed to psilocybin or the nicotine patch. This is consistent with growing evidence that psilocybin, when administered in a controlled clinical setting with proper screening and supervision, has a favorable safety profile.
Who Benefits Most
This study enrolled psychiatrically healthy adult smokers who wanted to quit, so the findings apply most directly to motivated smokers without major psychiatric conditions. The psilocybin session was conducted in a carefully controlled environment with trained facilitators, which is key. This is not about recreational use. The trial tested a single session combined with weeks of structured therapy, so the results apply to that combination, not to psilocybin alone. People who have tried and failed with standard treatments like patches, gums, or medications may find the most hope in these findings, though more research is needed to confirm which populations respond best.
Practical Takeaways
- Psilocybin-assisted therapy is still experimental and not yet approved for smoking cessation, so do not attempt this outside of a clinical trial or supervised medical setting.
- If you are trying to quit smoking, cognitive behavioral therapy remains a proven approach that helped both groups in this study and is widely available today.
- Talk to your doctor about all available options, including prescription medications like varenicline and bupropion, which have strong evidence for helping people quit.
- Watch for upcoming clinical trials if psilocybin-assisted therapy interests you, as several larger studies are now in progress at major research centers.
Related Studies and Research
- Psilocybin-assisted therapy: Johns Hopkins trial shows major depression relief covers another landmark Johns Hopkins study on psilocybin for mental health.
FAQs
How does psilocybin help people quit smoking?
Researchers believe psilocybin works differently from traditional cessation aids like nicotine patches. Instead of replacing nicotine, psilocybin appears to create a window of heightened psychological flexibility. During the supervised session, participants often report profound shifts in perspective about their relationship with smoking. This psychological “reset,” combined with weeks of cognitive behavioral therapy, may help break deeply ingrained habits in a way that nicotine replacement alone cannot. The exact brain mechanisms are still being studied, but early imaging research suggests psilocybin disrupts rigid patterns of thinking tied to addiction.
Is psilocybin therapy for smoking cessation available to the public?
Not yet. Psilocybin remains a Schedule I controlled substance in the United States, which means it cannot be legally prescribed outside of approved research studies. The FDA has granted “breakthrough therapy” designation to psilocybin for depression, which speeds up the review process, but no such designation exists yet specifically for smoking cessation. Several organizations are working to expand clinical trials, and some states like Oregon have created frameworks for supervised psilocybin use. However, it will likely be several years before psilocybin-assisted smoking cessation therapy becomes widely available through standard medical channels.
What made this study different from previous psilocybin smoking research?
The earlier pilot on psilocybin for smoking cessation was an open-label study of 15 people with no comparison group. This Johns Hopkins trial randomized people to psilocybin or an established active treatment, the nicotine patch, and both groups received the same cognitive behavioral therapy. It was still unblinded, so participants knew what they received, which makes it hard to separate the drug effect from expectations. A larger trial is needed to confirm these results.
Bottom Line
This pilot trial from Johns Hopkins provides compelling early evidence that psilocybin-assisted therapy could be a powerful tool for smoking cessation. A single supervised psilocybin session, combined with cognitive behavioral therapy, helped four times as many smokers stay quit at 6 months compared to standard nicotine patch therapy. While larger trials are needed before this becomes a mainstream treatment, the six-fold advantage in abstinence odds and the absence of serious adverse events attributed to treatment make a strong case for continued research into psychedelic-assisted approaches to addiction.
